Literature DB >> 19926013

Genotype-phenotype aspects of type 2 long QT syndrome.

Wataru Shimizu1, Arthur J Moss, Arthur A M Wilde, Jeffrey A Towbin, Michael J Ackerman, Craig T January, David J Tester, Wojciech Zareba, Jennifer L Robinson, Ming Qi, G Michael Vincent, Elizabeth S Kaufman, Nynke Hofman, Takashi Noda, Shiro Kamakura, Yoshihiro Miyamoto, Samit Shah, Vinit Amin, Ilan Goldenberg, Mark L Andrews, Scott McNitt.   

Abstract

OBJECTIVES: The purpose of this study was to investigate the effect of location, coding type, and topology of KCNH2(hERG) mutations on clinical phenotype in type 2 long QT syndrome (LQTS).
BACKGROUND: Previous studies were limited by population size in their ability to examine phenotypic effect of location, type, and topology.
METHODS: Study subjects included 858 type 2 LQTS patients with 162 different KCNH2 mutations in 213 proband-identified families. The Cox proportional-hazards survivorship model was used to evaluate independent contributions of clinical and genetic factors to the first cardiac events.
RESULTS: For patients with missense mutations, the transmembrane pore (S5-loop-S6) and N-terminus regions were a significantly greater risk than the C-terminus region (hazard ratio [HR]: 2.87 and 1.86, respectively), but the transmembrane nonpore (S1-S4) region was not (HR: 1.19). Additionally, the transmembrane pore region was significantly riskier than the N-terminus or transmembrane nonpore regions (HR: 1.54 and 2.42, respectively). However, for nonmissense mutations, these other regions were no longer riskier than the C-terminus (HR: 1.13, 0.77, and 0.46, respectively). Likewise, subjects with nonmissense mutations were at significantly higher risk than were subjects with missense mutations in the C-terminus region (HR: 2.00), but that was not the case in other regions. This mutation location-type interaction was significant (p = 0.008). A significantly higher risk was found in subjects with mutations located in alpha-helical domains than in subjects with mutations in beta-sheet domains or other locations (HR: 1.74 and 1.33, respectively). Time-dependent beta-blocker use was associated with a significant 63% reduction in the risk of first cardiac events (p < 0.001).
CONCLUSIONS: The KCNH2 missense mutations located in the transmembrane S5-loop-S6 region are associated with the greatest risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926013      PMCID: PMC2808400          DOI: 10.1016/j.jacc.2009.08.028

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

Review 1.  Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2.

Authors:  C T January; Q Gong; Z Zhou
Journal:  J Cardiovasc Electrophysiol       Date:  2000-12

2.  Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.

Authors:  P J Schwartz; S G Priori; C Spazzolini; A J Moss; G M Vincent; C Napolitano; I Denjoy; P Guicheney; G Breithardt; M T Keating; J A Towbin; A H Beggs; P Brink; A A Wilde; L Toivonen; W Zareba; J L Robinson; K W Timothy; V Corfield; D Wattanasirichaigoon; C Corbett; W Haverkamp; E Schulze-Bahr; M H Lehmann; K Schwartz; P Coumel; R Bloise
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

3.  Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.

Authors:  I Splawski; J Shen; K W Timothy; M H Lehmann; S Priori; J L Robinson; A J Moss; P J Schwartz; J A Towbin; G M Vincent; M T Keating
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

4.  Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.

Authors:  W Shimizu; C Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

5.  Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome.

Authors:  A J Moss; W Zareba; W J Hall; P J Schwartz; R S Crampton; J Benhorin; G M Vincent; E H Locati; S G Priori; C Napolitano; A Medina; L Zhang; J L Robinson; K Timothy; J A Towbin; M L Andrews
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

6.  Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome.

Authors:  E Ficker; A T Dennis; C A Obejero-Paz; P Castaldo; M Taglialatela; A M Brown
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

7.  Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel.

Authors:  Arthur J Moss; Wojciech Zareba; Elizabeth S Kaufman; Eric Gartman; Derick R Peterson; Jesaia Benhorin; Jeffrey A Towbin; Mark T Keating; Silvia G Priori; Peter J Schwartz; G Michael Vincent; Jennifer L Robinson; Mark L Andrews; Changyong Feng; W Jackson Hall; Aharon Medina; Li Zhang; Zhiqing Wang
Journal:  Circulation       Date:  2002-02-19       Impact factor: 29.690

8.  Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

Authors:  Wojciech Zareba; Arthur J Moss; Gloria Sheu; Elizabeth S Kaufman; Silvia Priori; G Michael Vincent; Jeffrey A Towbin; Jesaia Benhorin; Peter J Schwartz; Carlo Napolitano; W Jackson Hall; Mark T Keating; Ming Qi; Jennifer L Robinson; Mark L Andrews
Journal:  J Cardiovasc Electrophysiol       Date:  2003-11

9.  Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan.

Authors:  Wataru Shimizu; Minoru Horie; Seiko Ohno; Kotoe Takenaka; Masato Yamaguchi; Masami Shimizu; Takashi Washizuka; Yoshifusa Aizawa; Kazufumi Nakamura; Tohru Ohe; Takeshi Aiba; Yoshihiro Miyamoto; Yasunao Yoshimasa; Jeffrey A Towbin; Silvia G Priori; Shiro Kamakura
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

10.  Risk stratification in the long-QT syndrome.

Authors:  Silvia G Priori; Peter J Schwartz; Carlo Napolitano; Raffaella Bloise; Elena Ronchetti; Massimiliano Grillo; Alessandro Vicentini; Carla Spazzolini; Janni Nastoli; Georgia Bottelli; Roberta Folli; Donata Cappelletti
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245

View more
  85 in total

1.  Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome.

Authors:  Matthew R Stump; Qiuming Gong; Zhengfeng Zhou
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

2.  Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.

Authors:  Alon Barsheshet; Arthur J Moss; Scott McNitt; Slava Polonsky; Coeli M Lopes; Wojciech Zareba; Jennifer L Robinson; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Jeffrey A Towbin; G Michael Vincent; Ming Qi; Ilan Goldenberg
Journal:  Circ Cardiovasc Genet       Date:  2011-08-10

Review 3.  Short and long QT syndromes: does QT length really matter?

Authors:  Jean-Philippe Couderc; Coeli M Lopes
Journal:  J Electrocardiol       Date:  2010 Sep-Oct       Impact factor: 1.438

4.  Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals.

Authors:  Ilan Goldenberg; Samuel Horr; Arthur J Moss; Coeli M Lopes; Alon Barsheshet; Scott McNitt; Wojciech Zareba; Mark L Andrews; Jennifer L Robinson; Emanuela H Locati; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Carlo Napolitano; Pyotr G Platonov; Silvia G Priori; Ming Qi; Peter J Schwartz; Wataru Shimizu; Jeffrey A Towbin; G Michael Vincent; Arthur A M Wilde; Li Zhang
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

5.  Inhibition of nonsense-mediated mRNA decay by antisense morpholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome.

Authors:  Qiuming Gong; Matthew R Stump; Zhengfeng Zhou
Journal:  J Mol Cell Cardiol       Date:  2010-10-28       Impact factor: 5.000

Review 6.  Genetics of sudden cardiac death caused by ventricular arrhythmias.

Authors:  Roos F Marsman; Hanno L Tan; Connie R Bezzina
Journal:  Nat Rev Cardiol       Date:  2013-12-10       Impact factor: 32.419

7.  An Interdomain KCNH2 Mutation Produces an Intermediate Long QT Syndrome.

Authors:  Marika L Osterbur; Renjian Zheng; Robert Marion; Christine Walsh; Thomas V McDonald
Journal:  Hum Mutat       Date:  2015-06-13       Impact factor: 4.878

Review 8.  Genetics of long QT syndrome.

Authors:  David J Tester; Michael J Ackerman
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Jan-Mar

9.  Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study.

Authors:  Arthur A M Wilde; Arthur J Moss; Elizabeth S Kaufman; Wataru Shimizu; Derick R Peterson; Jesaia Benhorin; Coeli Lopes; Jeffrey A Towbin; Carla Spazzolini; Lia Crotti; Wojciech Zareba; Ilan Goldenberg; Jørgen K Kanters; Jennifer L Robinson; Ming Qi; Nynke Hofman; David J Tester; Connie R Bezzina; Marielle Alders; Takeshi Aiba; Shiro Kamakura; Yoshihiro Miyamoto; Mark L Andrews; Scott McNitt; Bronislava Polonsky; Peter J Schwartz; Michael J Ackerman
Journal:  Circulation       Date:  2016-08-26       Impact factor: 29.690

10.  Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.

Authors:  Matthew D Perry; Chai Ann Ng; Kevin Phan; Erikka David; Kieran Steer; Mark J Hunter; Stefan A Mann; Mohammad Imtiaz; Adam P Hill; Ying Ke; Jamie I Vandenberg
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.